There's another door into this disease, another way to interrupt the cascade
For the roughly three million Americans whose severe asthma resists every available treatment, medicine has long faced a stubborn wall. A research team led by Michael Wechsler at National Jewish Health has now published results in the New England Journal of Medicine suggesting that itepekimab, a monoclonal antibody targeting the inflammatory protein interleukin-33, opens a previously unexplored door into the disease — reducing asthma control loss nearly in half compared to placebo over a twelve-week trial. The finding matters not only as a potential new therapy, but as evidence that the biology of asthma is wider and more navigable than the existing treatment map has suggested.
- Three million Americans with severe asthma remain inadequately treated despite the strongest drugs medicine currently offers, creating a quiet, chronic crisis of breathlessness and diminished life.
- Itepekimab targets interleukin-33, an inflammatory pathway that existing monoclonal antibodies have left entirely untouched — a meaningful departure from the crowded field of asthma biologics.
- In a 70-site international trial, patients receiving itepekimab saw asthma control loss fall to 22 percent, compared to 41 percent in the placebo group, with measurable gains in lung function.
- The combination of itepekimab and dupilumab did not outperform either drug alone, raising unresolved questions about how these pathways interact and which patients benefit from which approach.
- Researchers now face the harder work of identifying which patient profiles respond best, with phase 3 trials required before the FDA would consider approval — meaning relief for waiting patients remains years away.
Michael Wechsler and his team at National Jewish Health's Cohen Family Asthma Institute set out to address a persistent failure in medicine: a stubborn subset of the roughly three million Americans with severe asthma simply does not improve, even when treated with the most powerful available drugs. Rather than revisiting the same inflammatory targets — interleukins 4, 5, and 13 — that existing monoclonal antibodies already address, Wechsler's international research group designed itepekimab to interrupt a different pathway entirely, one involving interleukin-33, a protein previously overlooked in asthma treatment.
The phase 2 trial enrolled adults with moderate-to-severe asthma inadequately controlled by standard inhaled therapies across 70 sites worldwide. Participants were divided into four groups — itepekimab alone, dupilumab alone, both drugs combined, or placebo — and received injections every two weeks for twelve weeks. The results were encouraging: while 41 percent of placebo patients experienced a measurable loss of asthma control, only 22 percent of those on itepekimab did. Lung function also improved. The findings were published in the New England Journal of Medicine.
Wechsler was measured in his optimism. The trial offered genuine new insight into asthma's molecular architecture and confirmed that interleukin-33 represents a real and targetable pathway — but not every patient in the itepekimab group responded dramatically, and the combination arm did not outperform either drug alone. The critical questions now are which patients are most likely to benefit, and whether biomarkers can help predict that response. Phase 3 trials will be necessary before any FDA approval process can begin. For millions of patients who have exhausted their options, itepekimab is a door newly opened — but the passage through it remains a work in progress.
Michael Wechsler's team at the National Jewish Health Cohen Family Asthma Institute had a problem to solve: roughly three million Americans with severe asthma were not getting better, even when doctors threw the strongest available medications at them. The standard treatments—corticosteroids, the monoclonal antibodies dupilumab and mepolizumab and benralizumab—worked well enough for many patients, but for a stubborn subset, the airways kept narrowing, kept inflaming, kept refusing to cooperate. Wechsler and his international research group decided to chase a different target entirely. Instead of going after the same inflammatory proteins everyone else was chasing, they designed a new monoclonal antibody called itepekimab to interrupt a pathway involving interleukin-33, a protein that hadn't been the focus of asthma treatment before.
The trial was straightforward in design but ambitious in scope. Researchers at 70 sites across multiple countries enrolled adults between 18 and 70 who had moderate-to-severe asthma that wasn't well controlled despite being on inhaled corticosteroids and long-acting beta-agonists—the standard two-drug combination. They divided the participants into four groups: one received itepekimab alone, another got dupilumab alone, a third received both drugs together, and the fourth got placebo. Everyone received their assigned treatment by injection every two weeks for twelve weeks. The question was simple: would itepekimab work?
The numbers came back encouraging. In the placebo group, 41 percent of patients experienced a loss of asthma control—a measurable worsening that meant the disease was slipping backward. In the itepekimab group, that figure dropped to 22 percent. The dupilumab-alone group saw 19 percent experience control loss, and the combination group landed at 27 percent. Beyond just preventing deterioration, itepekimab also improved how well patients' lungs actually functioned, a concrete measure of breathing capacity. The results were clean enough and consistent enough that the team published them in the New England Journal of Medicine, one of the most rigorous venues in medical publishing.
What made this finding significant wasn't just that a new drug worked—it was that it worked by targeting something different. Asthma is fundamentally a disease of inflammation and airway sensitivity, a chronic condition where the lungs overreact to ordinary stimuli. The existing arsenal of monoclonal antibodies had focused on a few key inflammatory proteins: interleukin-4, interleukin-5, and interleukin-13. Those drugs had proven their worth. But they didn't help everyone. By targeting interleukin-33 instead, Wechsler's team was essentially saying: there's another door into this disease, another way to interrupt the cascade of inflammation that leaves some patients gasping.
Wechsler himself was cautious in his optimism. He noted that the trial gave researchers new insight into how asthma actually works at the molecular level, and that itepekimab represented a genuine new option for patients who had run out of good choices. But he also acknowledged the obvious next question: which patients would benefit most? Not everyone in the itepekimab group improved dramatically. Some still lost control of their asthma. The work ahead would involve figuring out whether there were biomarkers or patient characteristics that could predict who would respond to this new pathway. Phase 3 trials—larger, longer studies needed before the FDA would consider approval—would have to answer that question. For now, the door had opened. Three million Americans with severe asthma were still waiting to see if itepekimab might be the key that finally fit their particular lock.
Citações Notáveis
We have targeted a new pathway that may potentially interrupt the inflammatory cascade and improve care in asthma patients.— Dr. Michael E. Wechsler, director of the National Jewish Health Cohen Family Asthma Institute
We still need to ascertain which patients are most likely to respond to this novel therapy.— Dr. Michael E. Wechsler
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this targets interleukin-33 specifically? Aren't the existing drugs already working for most people?
They are, but not for everyone. About ten percent of asthma patients have the severe form, and many of those don't respond to the drugs that target interleukin-4, 5, and 13. It's like having a lock that three different keys can open—but some locks are different. This one targets a pathway those other drugs don't touch.
So this is for people who've already failed other treatments?
Exactly. These are patients on the maximum doses of corticosteroids and other standard therapies, and they're still struggling to breathe. For them, a new pathway isn't just nice to have—it's urgent.
The numbers show 22 percent still lost control even on itepekimab. That's not a cure.
No, it's not. But it's better than 41 percent on placebo. And the lung function improved measurably. For someone who's been fighting their own lungs for years, that's meaningful. The real question now is figuring out which patients are most likely to be in that 78 percent who do improve.
How long until patients can actually get this drug?
That's the waiting game. They need phase 3 trials first—bigger, longer studies. Then FDA review. We're probably looking at years, not months. But the fact that it's safe and shows efficacy in phase 2 means the path forward exists.
What does this tell us about asthma that we didn't know before?
That the inflammatory cascade in asthma is more complex than we thought. There's not just one switch to flip. There are multiple pathways, and some patients' disease runs on different wiring than others. That's actually hopeful—it means there are more levers to pull.